If you or a loved one is taking Tysabri for multiple sclerosis or Crohn's disease, you may be concerned about the risk of progressive multifocal leukoencephalopathy (PML). This serious brain infection has been linked to natalizumab, especially in patients with certain risk factors. Building on years of clinical research and pharmacovigilance, this page explains who may be at higher risk and what monitoring is recommended.
Tysabri (natalizumab) is a biologic medication approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. The U.S. Food and Drug Administration (FDA) has assigned a boxed warning to Tysabri, the agency's most stringent safety alert, due to this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically leads to death or severe disability, and the warning emphasizes that healthcare professionals must monitor patients closely for any new signs or symptoms suggestive of the infection (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Clinical presentation of PML can include progressive weakness on one side of the body, clumsiness, visual disturbances, changes in thinking or memory, and personality changes. Diagnosis is confirmed through brain imaging, typically magnetic resonance imaging (MRI), and detection of JC virus DNA in cerebrospinal fluid via polymerase chain reaction (PCR). The infection is often fatal, and survivors may be left with permanent neurological deficits.
The mechanistic pathway linking Tysabri to PML involves the drug's action as an alpha-4 integrin antagonist. Tysabri blocks the adhesion molecule VLA-4 on immune cells, preventing their migration from the bloodstream into the brain. This reduces inflammation in multiple sclerosis but also impairs normal immune surveillance against the JC virus. In immunocompromised patients, the virus can reactivate and infect oligodendrocytes, leading to demyelination and the characteristic lesions of PML. Three established risk factors for developing PML while on Tysabri have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressant medications (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk. The FDA-approved labeling states that these factors should be considered in the context of expected benefit when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the PML risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients must be enrolled in this program, read the Medication Guide, understand the risks, and sign a Patient Enrollment Form. Pharmacies and infusion centers must be specially certified to dispense or infuse Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The labeling instructs healthcare professionals to withhold Tysabri immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
For patients in Georgia who have developed PML after taking Tysabri, legal considerations may arise regarding the adequacy of warnings provided by the manufacturer. The FDA boxed warning clearly states the risk, but questions can center on whether prescribers and patients were fully informed about the specific risk factors and the need for vigilant monitoring. The timeline between exposure to Tysabri and documented harm is critical. PML can occur after varying durations of treatment, with risk increasing after two years of therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who developed PML may have experienced delays in diagnosis if symptoms were not promptly recognized. In Georgia, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally two years from the date the injury was discovered or reasonably should have been discovered. For medical malpractice claims, the statute may be two years from the date of the act or omission, with a maximum of five years from the date of the negligent act. However, these time limits can vary based on specific circumstances, such as the patient's age or mental capacity. It is essential for affected individuals to consult with an attorney experienced in pharmaceutical litigation to understand the applicable deadlines. Attorney-related considerations for affected patients include the need to gather medical records documenting the diagnosis of PML, the timeline of Tysabri treatment, and any evidence of inadequate warnings or monitoring. Legal claims may be based on failure to warn, defective design, or negligence. The risk-benefit analysis that physicians must perform when prescribing Tysabri is outlined in the labeling, which states that physicians should consider whether the expected benefit is sufficient to offset the PML risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). If a patient was not adequately informed of this risk, or if monitoring was not performed as recommended, legal recourse may be available.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Request archival records or inquire about member-exclusive transition and benefit programs.
In Georgia, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally two years from the date the injury was discovered or reasonably should have been discovered. For medical malpractice claims, the statute may be two years from the date of the act or omission, with a maximum of five years from the date of the negligent act. However, these time limits can vary based on specific circumstances, such as the patient's age or mental capacity. It is essential to consult with an attorney experienced in pharmaceutical litigation to understand the applicable deadlines.
Three established risk factors for developing PML while on Tysabri have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressant medications (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk.
If you or a loved one developed PML after taking Tysabri, it is important to seek medical care immediately and consult with an attorney experienced in pharmaceutical litigation. Gather medical records documenting the diagnosis of PML, the timeline of Tysabri treatment, and any evidence of inadequate warnings or monitoring. Legal claims may be based on failure to warn, defective design, or negligence. The FDA boxed warning clearly states the risk, but questions can center on whether prescribers and patients were fully informed about the specific risk factors and the need for vigilant monitoring.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Individuals with documented archive exposure and a related diagnosis may request an independent, no-cost eligibility review.